Chantix to be Tested for Anti-Addiction Possibilities
A report published today claims that clinical trials will begin next month to see if Pfizer's stop smoking drug, Chantix, can be an effective treatment for curbing drinking and gambling habits. The drug has been shown to be effective in treating smoking addiction, but has been met with widespread controversy over a possible link to neuropsychiatric events, including suicidal ideation and suicidal action. Dr. Selena Bartlett, who claims that Chantix has reduced alcohol consumption in rates by 50 percent, will be heading up the study. Read more...
Writer Gives First-Hand Account of Chantix Experiences
A writer for New York Magazine recently published an article entitled, "My Brain on Chantix," revealing his personal experiences while taking Chantix. Derek de Koff says in the article that he never believed the stories of Chantix contributing to the tragic shooting death of Carter Albrecht, that is until he began taking the drug himself. Chantix has been hailed by many as a "miracle drug," but others have reported serious side effects ranging from vivid and frightening dreams to suicidal behavior. In the article de Koff chronicles his experiences with Chantix from start to finish. Read more...
Chantix: FDA Warns of Neuropsychiatric Symptoms
February 06, 2008 - On Friday the FDA issue a Public Health Advisory for Pfizer's popular smoking cessation drug Chantix. This advisory comes just two months after an Early Communication advised physicians of a possible link between Chantix and neuropsychiatric symptoms. The FDA has now said that it is becoming increasingly likely that this association exists. The shooting death of Dallas musician Carter Albrecht, reportedly to be linked to Chantix, triggered public awareness and controversy about the drug. Since then numerous claims of aggression, depression, suicidal ideation and even suicidal action have been reported. Read more...
Reich & Binstock Chantix Client In the News
January 02, 2008 - Last week the CBS evening news featured a story on the possible relationship between Pfizer's smoking cessation drug Chantix and an increased risk of suicide. The story was centered on 33 year-old Amy Garza. Garza claims that shortly after starting Chantix she began to have mental problems. Garza made an attempt to take her own life shortly thereafter. Read more...
Chantix is developed by Pfizer to help people quit smoking. Severe side-effects have been reported by users of Chantix, including joint and muscle pain, suicidal thoughts, depression, crying for no reason, panic, agitation, lack of concentration and most seriously, psychotic behavior.